GlassScriptPhysician profile
Tyler W Kuhk
NPI 1467810283
$32,782.57
in general payments reported to CMS, 2019-2025
11 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,570 · 2022: $1,233 · 2023: $3,350 · 2024: $6,979 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,628 · Travel and Lodging: $4,773 · Food and Beverage: $2,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,784.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,628.00 |
| Travel and Lodging | $4,773.28 |
| Food and Beverage | $2,793.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $15,562.07 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $8,987.50 | 2021-2025 | Breztri, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $5,483.14 | 2022-2025 | Dupixent |
| Mylan Specialty L.P. | $1,041.31 | 2021 | |
| Glaxosmithkline, LLC. | $415.53 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $400.00 | 2023-2024 | |
| United Therapeutics Corporation | $362.49 | 2021-2025 | Steen Solution |
| Pulmonx Corporation | $197.16 | 2024 | Zephyr Endobronchial Valve |
| Verona Pharma, INC. | $195.04 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $74.99 | 2022 | |
| Viatris Specialty LLC | $63.34 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Kuhk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.